Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
奥麦罗制药的股票在公司宣布Narsoplimab达到了其主要试验终点,并将重新向FDA提交Narsoplimab生物制品许可申请后上涨。
Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
Omeros宣布纳索普利单抗达到其主要试验终点并将向美国食品药品管理局重新提交纳索普利单抗生物制剂许可证申请后,该公司股价走高。